ADX-914 is under clinical development by Q32 Bio and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase II drugs for Atopic Dermatitis (Atopic Eczema) have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ADX-914’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ADX-914 overview

ADX-914 is under development for the treatment of autoimmune, atopic dermatitis and inflammatory diseases. It acts by targeting interleukin-7 receptor (IL-7R) and thymic stromal lymphopoietin (TSLP). It is a fully human monoclonal antibody.

Q32 Bio overview

Q32 Bio, formerly Admirx, is a bio pharmaceutical manufacturing company based in the US. The company is engaged in the manufacture of therapeutic drugs for restoring immune homeostasis. The innate immunity includes the complement system, which can be activated in three ways by cleaving component proteins like Complement Component 3 (C3) into smaller protein fragments. These protein fragments perform a variety of functions, including cell debris clearance, pathogenic intruder elimination, and adaptive immunity modulation. Q32 Bio is headquartered in Waltham, Massachusetts, the US.

For a complete picture of ADX-914’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.